Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7686MR)

This product GTTS-WQ7686MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7686MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10076MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ6051MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ6648MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ4011MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ10438MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ2919MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ10750MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ5452MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDA 1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW